While the proven efficacy of TRK inhibitors such as larotrectinib and entrectinib in fusion-positive tumours demonstrates that TRK signalling is a therapeutically targetable pathway, no clinical studies have yet confirmed similar responses in fusion-negative settings. Here, TPM3 is linked to neoplasm.